Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | LPL | P06858 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25559690 | 0.81 | ENPP2 (0.40) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL789866 | 0.81 | ENPP2 (0.70) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| Phenylboronic Acid SCHEMBL28428622 | 0.77 | ENPP2 (0.74) | ENPP2MGLLCA4CA6CA5A | |
| SCHEMBL22960487 | 0.76 | ENPP2 (0.41) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL31139484 | 0.74 | MGLL (0.86) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL30712840 | 0.74 | MGLL (0.86) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL12619984 | 0.74 | MGLL (0.86) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL8884 | 0.72 | ENPP2 (1.00) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL4933 | 0.72 | ENPP2 (0.58) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL29547555 | 0.72 | ENPP2 (0.58) | ENPP2KDM4EALDH1A1MGLLCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066381-A1 | ONE-POT, MULTI-COMPONENT MANUFACTURING METHOD FOR TETRAHYDROTHIENOPYRIDINE DERIVATIVES INCLUDING N-SUBSTITUTED AMINO ACIDS | MOLECULES & MATERIALS (KR) | 2025-02-27 | — | — | US | claimed |
| CN-112321585-B | Asymmetric substituted diphenyl pyridine compound and preparation and application thereof | 华南理工大学 | 2022-04-22 | — | — | CN | claimed |
| CN-112321585-A | Asymmetric substituted diphenyl pyridine compound and preparation and application thereof | 华南理工大学 | 2021-02-05 | — | — | CN | claimed |
| CN-112086564-A | Passivating agent and passivation method thereof and method for preparing semiconductor film | 杭州纤纳光电科技有限公司 | 2020-12-15 | — | — | CN | claimed |
| CN-111435705-A | Repairing agent and repairing method thereof and method for preparing photoelectric film | 杭州纤纳光电科技有限公司 | 2020-07-21 | — | — | CN | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| CN-122010938-A | Pyrido [1, 2-a ] pyrimidine mesoionic derivative containing five-membered heterocyclic structure, and preparation and application thereof | 贵州大学 | 2026-05-12 | — | — | CN | disclosed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| WO-2007136572-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136573-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| WO-2004039762-A1 | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
| WO-1999011129-A1 | ENANTIOMERICALLY ENRICHED COMPOSITIONS AND THEIR PESTICIDAL USE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015223-A1 | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | HTR5A, HTR2A, HTR3A | ENPP2 487/4885KDM4E 3183/4885ALDH1A1 1918/4885 |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | GPR119, GPR65, FFAR4 | ENPP2 1521/4885KDM4E 2399/4885ALDH1A1 2576/4885 |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | ENPP2 1143/4885KDM4E 1355/4885ALDH1A1 4167/4885 |
| US-20250066381-A1 | ONE-POT, MULTI-COMPONENT MANUFACTURING METHOD FOR TETRAHYDROTHIENOPYRIDINE DERIVATIVES INCLUDING N-SUBSTITUTED AMINO ACIDS | TBXAS1, TASP1, GART | ENPP2 4126/4885KDM4E 3647/4885ALDH1A1 1131/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | ENPP2 4213/4885KDM4E 525/4885ALDH1A1 3566/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | ENPP2 854/4885KDM4E 1589/4885ALDH1A1 1749/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | ENPP2 2131/4885KDM4E 1798/4885ALDH1A1 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.